MetaCap

Addex Therapeutics (ADXN) vs GT Biopharma (GTBP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

GT Biopharma is the larger company by market cap ($6.3 million vs $6.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADXN+10.86%GTBP-52.26%
+75%+8%-58%
Oct 7, 20261 yearNov 20, 2026
ADXN+7.81%GTBP-55.69%
+30%-15%-60%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADXN versus GTBP key metrics
MetricADXNGTBP
Share price$3.47$2.96
Market cap$6.08M$6.33M
1-day change+2.06%-6.92%
YTD return—+277.07%
1-year return—+303.27%
5-year return—-97.77%
EPS (TTM)$-7.56$-128.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-28.35M
52-week high$10.43$23.60
52-week low$2.56$2.87
Distance from 52-week high-66.73%-87.46%
Analyst consensus—none
Avg. price target upside—+2433.78%
Average volume383.35K78.16K
Shares outstanding1.75M2.14M
Employees31
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Addex Therapeutics

ADXN stock →

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

About GT Biopharma

GTBP stock →

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

ADXN vs GTBP FAQ

Which is bigger, Addex Therapeutics or GT Biopharma?

GT Biopharma (GTBP) is larger, with a market capitalization of $6.33M compared with $6.08M for Addex Therapeutics (ADXN).

Are Addex Therapeutics and GT Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons